Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3711627 | PMC |
| http://dx.doi.org/10.1086/593207 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Neonatal Late-Onset Sepsis Due to Acinetobacter baumannii: A Case Report.
Cureus
November 2024
Neonatology Department, Maternidade Daniel de Matos, Unidade Local de Saúde de Coimbra, Coimbra, PRT.
Late-onset sepsis (LOS) is commonly associated with pathogens acquired in hospital or community settings and carries a significant risk of morbidity and mortality in neonates. We present a case of a late preterm neonate, born at 36 weeks and 2 days with low birth weight (1700 g), who was admitted to the neonatal intensive care unit (NICU) and developed LOS on the fourth day of life. LOS was diagnosed in the context of fever and lethargy, mild thrombocytopenia, leukopenia, and lymphopenia, and was caused by multidrug-resistant (MDR) , confirmed through blood culture.
View Article and Find Full Text PDFPathogenic Burden, Antimicrobial Resistance Pattern and Clinical Outcome of Nosocomial Bloodstream Infections in Intensive Care Unit.
J Intensive Care Med
December 2024
Department of Critical Care and Anaesthesiology, All India Institute of Medical Sciences, Jodhpur, India.
Nosocomial bloodstream infections with multidrug-resistant microorganisms have become a common health threat in intensive care settings worldwide. Understanding antimicrobial resistance and the outcomes of these infections is crucial for addressing this issue. This study aimed to investigate the burden, antimicrobial resistance, and 28-day outcomes of nosocomial bloodstream infections in the intensive care unit.
View Article and Find Full Text PDFGene editing tool-loaded biomimetic cationic vesicles with highly efficient bacterial internalization for in vivo eradication of pathogens.
J Nanobiotechnology
December 2024
Beijing Institute of Radiation Medicine, 27 Taiping Road, Beijing, 100850, China.
In the post-COVID-19 era, drug-resistant bacterial infections emerge as one of major death causes, where multidrug-resistant Acinetobacter baumannii (MRAB) and drug-resistant Pseudomonas aeruginosa (DRPA) represent primary pathogens. However, the classical antibiotic strategy currently faces the bottleneck of drug resistance. We develop an antimicrobial strategy that applies the selective delivery of CRISPR/Cas9 plasmids to pathogens with biomimetic cationic hybrid vesicles (BCVs), irrelevant to bacterial drug resistance.
View Article and Find Full Text PDFA systematic review and meta-analysis: rising prevalence of colistin resistance in ICU-acquired Gram-negative bacteria.
APMIS
January 2025
Laboratory Sciences Research Center, Golestan University of Medical Sciences, Gorgan, Iran.
Colistin is a last-resort treatment for multidrug-resistant Gram-negative bacterial infections, particularly in critically ill patients. Nevertheless, it remains a major threat to public health. We assessed the proportion of colistin-resistant Gram-negative isolates from intensive care unit (ICU) infections in different years, areas, pathogens, and antimicrobial susceptibility tests (AST).
View Article and Find Full Text PDFIndividualized Antimicrobial Therapy using Antibiotic Combination Testing and Therapeutic Drug Monitoring to Treat Carbapenem-Resistant Acinetobacter baumannii Infection.
Int J Antimicrob Agents
December 2024
Department of Pharmacy, Singapore General Hospital, Singapore; Emerging Infectious Diseases, Duke-National University of Singapore Medical School, Singapore; Singhealth Duke-NUS Medicine Academic Clinical Programme, Singapore. Electronic address:
Article Synopsis
- - Treatment of multidrug resistant infections is tough because there aren't many effective antibiotics available, prompting the use of specialized strategies by pharmacists.
- - A two-part approach is used: in vitro antibiotic combination testing and therapeutic drug monitoring to tailor treatment, similar to precision medicine.
- - This method showed promising results in two patients with hard-to-treat Acinetobacter baumannii infections, using higher-than-recommended doses without causing any negative side effects.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!